

RNA-based gene therapy in autoimmune disease

The Problem

Immunosuppressive drugs are the standard-of-care for most autoimmune diseases. Current treatments cause significant adverse effects and morbidity. More selective treatments needed for refractory diseases.


The Solution

Our team is developing a new autoimmune therapy by targeting inflammatory cytokine signaling using mRNA-LNP delivery. This will enhance intracellular expression of target proteins to switch off damaging inflammatory signalling from subgroups of cytokines.

Our Program

- Progress: We have developed a PoC data showing increase in target expression using published mRNA-LNP formulations for delivery and assessed ability to switch off inflammatory cytokine signalling.

Seeking **funding and partnerships** with expertise in mRNA-LNP design and delivery



*= Target can be disclosed under a CDA

Our Team

Prof. Sandra Nicholson, Cytokine signalling
A/Prof. James Vince, Inflammation, mRNA-LNP

Onisha Patel, PhD, Business Development,
patel.o@wehi.edu.au